Fosun Wanbang (Jiangsu) Pharmaceutical Group is an innovation-driven pharmaceutical company in China and a core member of Fosun Pharma, with business spanning pharmaceutical R&D, manufacturing, wholesale and distribution across the healthcare industry chain. Several of its production lines have passed FDA and EU site audits, with key products including human insulins, GLP-1 products, EPO and heparin sodium, along with oral solid dosage products such as ticagrelor, tofacitinib, crizotinib and osimertinib tablets, and key APIs including insulins, heparin sodium, venetoclax and febuxostat.

コメントはありません。
評価とコメントを残す